Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

5.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
5.9K
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

114
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
114
Multicompartment Models: Overview01:14

Multicompartment Models: Overview

705
Multicompartment models are mathematical constructs that depict how drugs are distributed and eliminated within the body. They segment the body into several compartments, symbolizing various physiological or anatomical areas connected through drug transfer processes such as absorption, metabolism, distribution, and elimination.
These models offer a more comprehensive representation of drug behavior in the body than one-compartment models. They accommodate the complexity of drug distribution,...
705
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

11.3K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.3K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

1.3K
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cultural adaptation and psychometric validation of the Health Literacy Instrument for Adults with Tuberculosis (HELIA-TB) in India.

PloS one·2026
Same author

Influence of general practice education on medical students' attitude towards this discipline: a mixed studies scoping review protocol.

BMJ open·2026
Same author

Discrepancies in prescribed medications as reported by patients, general practitioners, and community pharmacists in older patients with polypharmacy in primary care.

BMC primary care·2026
Same author

Rethinking clinical trials in the multimorbidity era: the imperative for patient-centered tailored approaches.

Journal of clinical epidemiology·2026
Same author

The magnitude of multimorbidity in childhood: a global systematic review.

Systematic reviews·2026
Same author

General practitioner-pharmacist collaboration to enhance deprescribing of psychotropics, sedatives, and anticholinergics among older polypharmacy patients in primary care: study protocol of a cluster-randomized controlled trial (PARTNER).

Therapeutic advances in drug safety·2026

Related Experiment Video

Updated: Apr 24, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K

Current guidelines poorly address multimorbidity: pilot of the interaction matrix method.

Christiane Muth1, Hanna Kirchner2, Marjan van den Akker3

  • 1Institute of General Practice, Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany.

Journal of Clinical Epidemiology
|September 14, 2014
PubMed
Summary

A new framework helps identify and classify interactions between chronic heart failure (CHF) and other conditions. This matrix aids in managing multimorbidity by structuring complex disease-drug and drug-drug interactions.

Keywords:
Comorbidity [MeSH]Drug interactions [MeSH]Heart failure [MeSH]InteractionsMultimorbidityPractice guideline [MeSH]

More Related Videos

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

2.1K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K

Related Experiment Videos

Last Updated: Apr 24, 2026

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

21.0K
Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

2.1K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K

Area of Science:

  • Medical Informatics
  • Clinical Guideline Development
  • Multimorbidity Research

Background:

  • Chronic heart failure (CHF) frequently co-occurs with other conditions, complicating patient management.
  • Existing clinical guidelines often lack a structured approach to address these complex interactions.
  • Understanding inter-condition and treatment interactions is crucial for effective multimorbidity care.

Purpose of the Study:

  • To develop a novel framework for identifying and classifying interactions among treatments and conditions.
  • To apply and validate this framework using guidelines for chronic heart failure (CHF) and its common comorbidities.
  • To create an interaction matrix to visualize these complex relationships.

Main Methods:

  • Systematic text analysis of 48 evidence-based clinical practice guidelines for CHF and 18 co-occurring conditions.
  • Extraction of data on interactions, including disease-disease (Di-Di-I), disease-drug (Di-D-I), and drug-drug interactions (DDI), as well as synergistic treatments.
  • Development and refinement of a classification framework and an interaction matrix, with interrater reliability testing.

Main Results:

  • A total of 247 interactions were identified across the analyzed guidelines.
  • The identified interactions comprised 68 Di-Di-I, 115 Di-D-I, 12 DDI, and 52 synergistic treatments.
  • All 18 evaluated comorbidities exhibited at least one interaction with CHF, highlighting the pervasiveness of multimorbidity.

Conclusions:

  • The developed interaction matrix offers a structured method for presenting diverse interactions between an index disease and its comorbidities.
  • Guideline developers can utilize this matrix to enhance clinical decision-making in patients with multimorbidity.
  • Further research is warranted to establish the framework's impact on improving clinical guidelines and patient health outcomes.